CADILAHC:NSE-Cadila Healthcare Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 460.55

Change

+6.35 (+1.40)%

Market Cap

INR 476.30B

Volume

2.06M

Avg Analyst Target

INR 621.50 (+34.95%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Cadila Healthcare Limited (CADILAHC) Stock Analysis:
Based on the Cadila Healthcare Limited stock forecasts from 7 analysts, the average analyst target price for Cadila Healthcare Limited is INR 621.50 over the next 12 months. Cadila Healthcare Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Cadila Healthcare Limited is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, Cadila Healthcare Limited’s stock price was INR 460.55. Cadila Healthcare Limited’s stock price has changed by -1.55 % over the past week, -34.95 % over the past month and -0.52 % over the last year.

About

Cadila Healthcare Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It offers finished dosage human formulations comprising generics, branded generics, and speci ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-02 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+20.90 (+2.80%)

INR1,808.14B 29.97 18.57
DIVISLAB:NSE Divi's Laboratories Limited

+25.10 (+0.53%)

INR1,295.17B 60.63 39.54
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+56.40 (+1.22%)

INR775.58B 39.98 18.56
PEL:NSE Piramal Enterprises Limited

+41.20 (+1.66%)

INR577.17B 49.59 14.15
ALKEM:NSE Alkem Laboratories Limited

+32.30 (+0.94%)

INR429.65B 25.23 18.39
LUPIN:NSE Lupin Limited

+4.20 (+0.48%)

INR401.78B 25.10 32.25
AUROPHARMA:NSE Aurobindo Pharma Limited

+10.95 (+1.65%)

INR386.87B 7.42 4.87
LAURUSLABS:NSE Laurus Labs Limited

+8.50 (+1.67%)

INR272.94B 27.08 17.40
IPCALAB:NSE Ipca Laboratories Limited

+3.30 (+0.16%)

INR266.41B 54.17 17.46
AJANTPHARM:NSE Ajanta Pharma Limited

+38.35 (+1.84%)

INR180.02B 25.57 16.60

ETFs Containing CADILAHC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.73% 34% F 16% F
Dividend Return 0.73% 63% D 37% F
Total Return -3.00% 35% F 16% F
Trailing 12 Months  
Capital Gain -0.52% 37% F 14% F
Dividend Return 0.76% 63% D 35% F
Total Return 0.24% 37% F 13% F
Trailing 5 Years  
Capital Gain 16.36% 37% F 45% F
Dividend Return 3.46% 65% D 40% F
Total Return 19.82% 37% F 44% F
Average Annual (5 Year Horizon)  
Capital Gain 11.64% 28% F 46% F
Dividend Return 0.61% 56% F 45% F
Total Return 12.26% 26% F 45% F
Risk Return Profile  
Volatility (Standard Deviation) 42.75% 68% D+ 67% D+
Risk Adjusted Return 28.67% 35% F 54% F
Market Capitalization 476.30B 94% A 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 9.93 81% B- 73% C
Price/Book Ratio 2.90 56% F 37% F
Price / Cash Flow Ratio 14.46 56% F 35% F
EV/EBITDA 13.79 56% F 46% F
Management Effectiveness  
Return on Equity 15.40% 55% F 64% D
Return on Invested Capital 14.09% 63% D 80% B-
Return on Assets 6.71% 51% F 68% D+
Debt to Equity Ratio 4.69% 50% F 65% D
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.60 65% D 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector